TrialRespiratory research2018

A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.

Edward M Kerwin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.